tislelizumab + total neoadjuvant therapy

This combination regimen is an investigational treatment for locally advanced rectal cancer (LARC) that integrates the anti-PD-1 monoclonal antibody **tislelizumab** into a **Total Neoadjuvant Therapy (TNT)** framework. The TNT component typically consists of six weeks of capecitabine-based chemoradiotherapy (nCRT) followed by consolidation chemotherapy with eight cycles of mFOLFOX6 (modified fluorouracil, leucovorin, and oxaliplatin). The regimen is being evaluated in the Phase II **TOTAL trial**, led by investigator Baruch Brenner, to determine if the addition of immunotherapy to standard TNT can increase the rate of clinical complete response (cCR) and facilitate organ preservation, thereby avoiding the need for total mesorectal excision (TME) surgery.

Other names

TNT-brenner baruch-rectal cancerTislelizumab + TNTTislelizumab + mFOLFOX6 + capecitabine + radiation therapy